Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trialAndrew R. Clamp, Jonathan A. Ledermann, Elizabeth C James et al.|The Lancet|2019Cited by 223
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety reportAlicia Okines, David Cunningham, Michel Seymour et al.|Annals of Oncology|2012Cited by 67
Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian CancerSarah P. Blagden, Hani Gabra, Anne Hamilton et al.|Clinical Cancer Research|2018Cited by 66
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trialAndrew R. Clamp, Jonathan A. Ledermann, Elizabeth C James et al.|The Lancet Oncology|2022Cited by 45
Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trialsAlicia Okines, Andrew Wotherspoon, David González de Castro et al.|European Journal of Cancer|2013Cited by 40